300 The American Road
United States - Map
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The companys antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
|Immunomedics Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 3. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 1; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. David M. Goldenberg ,
Founder, Chairman of The Board and Director of IBC Pharmaceuticals Inc
|Ms. Cynthia L. Sullivan ,
Chief Exec. Officer, Pres, Director and Pres of Ibc Pharmaceuticals Inc
|Mr. Peter P. Pfreundschuh ,
Chief Financial Officer and VP of Fin.
|Mr. Gerard G. Gorman ,
|Ms. Phyllis Parker ,
Director of Admin. and Sec.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|